MTNB
Matinas BioPharma Holdings, Inc.
There isn't enough reported data to score MTNB yet.
MTNB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
MTNB's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
MTNB PE Valuation
MTNB has no meaningful PE right now: it lost money over the past year.
MTNB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect MTNB's losses to grow, with revenue growing.
MTNB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$17.25 | +$40.35 |
| Q1 2026 | -$29.55 | +$27.60 |
| Q4 2025 | -$30.00 | +$44.70 |
| Q3 2025 | -$50.85 | +$14.40 |
| Q2 2025 | -$57.60 | +$17.40 |
| Q1 2025 | -$57.15 | +$25.35 |
| Q4 2024 | -$74.70 | +$7.80 |
| Q3 2024 | -$65.25 | +$14.82 |
MTNB is still losing money, but far less than before: $17.25 per share over the past year, against $97.50 at its worst in late 2019.
MTNB Quarterly Revenue
MTNB's revenue is shrinking: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2023 | -510% | N/A |
| Q4 2022 | -515% | N/A |
| Q3 2022 | -514% | N/A |
| Q2 2022 | -558% | N/A |
| Q1 2021 | -19060% | N/A |
| Q4 2020 | -10382% | N/A |
| Q3 2020 | -5848% | N/A |
MTNB's operating margin was −510% last quarter, up 18550 points from the same quarter a year ago.
MTNB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.8M | +$185K |
| Q1 2026 | -$1.6M | +$406K |
| Q1 2025 | -$2M | +$3.8M |
| Q4 2023 | -$4.6M | -$238K |
| Q3 2023 | -$4.4M | +$784.1K |
| Q4 2022 | -$4.3M | -$347.1K |
| Q3 2022 | -$5.2M | +$754.9K |
| Q4 2021 | -$4M | +$313.8K |
MTNB has burned cash in almost every quarter: −$6M over the past year, against −$14M the year before.
MTNB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +26% | +87.9K shares |
| 3 years | +47% | +137K shares |
| 5 years | +56% | +153K shares |
| Available history | +104% | +218K shares |
MTNB has 427,079 diluted shares, up 26% from a year ago.
MTNB Net Leverage
MTNB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MTNB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.3 | Oversold |
| Stochastic | 3.3 | Oversold |
MTNB's weekly RSI is 28 (oversold) and its Stochastic is 3 (oversold).
MTNB PE vs Healthcare Sector
MTNB has no meaningful PE right now: it lost money over the past year.
MTNB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.95 | 53% below |
| 20 week MA | $3.56 | 74% below |
| 50 week MA | $7.25 | 87% below |
| 100 week MA | $11.2 | 92% below |
| 200 week MA | $98.4 | 99% below |
MTNB is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
MTNB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,485.0 | $703.4 | -53% |
| 2021 | $703.4 | $780.0 | +11% |
| 2022 | $780.0 | $389.3 | -50% |
| 2023 | $389.3 | $162.2 | -58% |
| 2024 | $162.2 | $7.77 | -95% |
| 2025 | $7.77 | $9.29 | +20% |
| 2026 YTD | $9.29 | $0.92 | -90% |
MTNB has finished lower in four of the last six years. It's down 90% so far in 2026.